胰岛素联合罗格列酮或二甲双胍随机对照治疗对2型糖尿病患者血清脂联素的影响被引量：3

Effects of insulin plus rosiglitazone or plus metformin on serum adiponectin in type 2 diabetes mellitus:A randomized-controlled study.

暂未订购

导出

摘要目的了解胰岛素联合罗格列酮或二甲双胍治疗对2型糖尿病患者血清脂联素水平及体脂分布的影响。方法将符合纳入标准的2型糖尿病患者60例,随机分成A、B两组。A组给予胰岛素联合罗格列酮(4mg/d,n=30)治疗,B组给予胰岛素联合二甲双胍治疗(n=30),共8周,治疗前后分别测量身高、体重、腰围、臀围、体重指数和腰臀比,血糖、糖化血红蛋白及血清脂联素等。结果胰岛素联合罗格列酮或二甲双胍治疗,均能降低血糖和糖化血红蛋白,减少胰岛素用量(P<0.05),罗格列酮治疗组血清脂联素水平升高明显(P<0.05),同时臀围、体重、体重指数增加(P<0.05),但腰围及腰臀比无明显变化(P>0.05)。二甲双胍治疗组血清脂联素水平、腰围、臀围、腰臀比、体重及体重指数均无明显改变(P>0.05)。结论罗格列酮治疗能升高2型糖尿病患者血清脂联素水平,改善体脂分布;二甲双胍治疗对2型糖尿病患者血清脂联素水平、体脂分布无明显影响。 Objective To study the effects of insulin plus rosiglitazone and insulin plus mefformin on serum adiponectin and body fat distribution in type 2 diabetes meUitus. Methods Sixty type 2 diabetic patients were recruited and divided into insulin plus rosiglitazone（4mg/d）group（ n = 30） and insulin plus mefformin group（ n = 30） randomly. The trial consisted for an 8 week course of treatment.The body weight,the waist circumstance,hip circumstance,ratio of waist to hip,body mass index（ BMI）,fasting blood glucose （FB）, postprandial plasma glucose PPG）, HbAlc, serum adiponectin, were measured at the beginning and at the end of 8 weeks. Result： The results revealed the level of FBG,PPG and HbAlc decreased obviously（ P 〈 0.05）, and the dosage of insulindecreased compared with the baseline（ P 〈 0.05） in beth insulin plus rosiglitazone group and insulin plus mefformin group.The hip circumstance,weight and BMI and the level of adiponectin increased significantly in insulin plus resiglitazone group（ P 〈 0.05）, but the waist circumstance and ratio of waist circumstance to hip circumstance did not change apparently（ P 〉 0.05）. On the other hand,in insulin plus mefformin group, the waist circumstance, hip circumstance, ratio of waist circumstance to hip circumstance, weight, BMI, and the level of serum adiponectin did not change significantly（ P 〉 0.05） when compared with the baseline. Conclusion Rosiglitazone can increase the level of serum adiponectin,it can improve body fat distribution in type 2 diabetes mellitus,mefformin have no effects on level of serum adiponectin and body fat distribution.

作者胡茂清田浩明张俭吴文莉周贤会赵万燕

机构地区四川省卫生管理干部学院四川大学华西医院内分泌科

出处《四川医学》 CAS 2007年第10期1082-1084,共3页 Sichuan Medical Journal

基金四川省卫生厅科研基金资助项目(WST060098)

关键词 2型糖尿病胰岛素罗格列酮二甲双胍联合治疗脂联素体脂分布 type 2 diabetes mellltus insulin rosiglitazone mefformin anited treatment adlponeetin body fat distribution

分类号 R587.1 [医药卫生—内分泌]

引文网络
相关文献

参考文献6

1Hotta K,Funahashi T,Bodkin NL,et al.Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitiaity during the progression to type 2 diabetes in rhesus monkeys[J].Diabetes,2001,50(2):1126
2Diez JJ,lglesias P.The role of the novel adipocyte-derived hormone adiponectin in human disease[J].Eur J Endocrinol,2003,148(3):293
3Philip KG,Gregorio D,Lu T,et al.Adiponectin expression from human adipose tissue:relation to obesity,insulin resistance and tumor necrosis-α expression[J].Diabetes,2003,52(7):1779
4邓宏明,刘红,邓华聪,宋英儒,陈卫.罗格列酮改善2型糖尿病患者体脂分布、脂联素水平和组织胰岛素敏感性[J].中华内分泌代谢杂志,2005,21(3):233-236. 被引量：20
5Hiroshi H,Toshihide K,Yukihiro Y,et al.Effects of pioglitazone on metabolic parameters,body fat distribution,and serum adiponectin levels in Janpan male patients with type 2 diabetes[J].Metabolism,2002,51(3):314
6Lefebvre AM,Laville M,Vega N,et al.Depot-specific differences in adipose tissue gene expression in lean and obese subjects[J].Diabetes,1998,47(1):98

二级参考文献15

1贾伟平,项坤三,丁炜,陆俊茜.男性中国人体脂分布与激素模式[J].中华内分泌代谢杂志,1998,14(2):78-81. 被引量：20
2DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol, 1979,237:E214-E223.
3Bergman RN, Van Citters GW, Mittelman SD, et al. Central role of the adipocyte in the metabolic syndrome. J Investig Med, 2001,49:119-126.
4Rebuffe-Scrive M, Bronnegard M, Nilsson A, et al. Steroid hormone receptors in human adipose tissues. J Clin Endocrinol Metab, 1990,71:1215-1219.
5Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev, 1994,74:761-811.
6Fasshauer M, Klein J, Neumann S, et al. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes. FEBS Lett, 2001,507:142-146.
7King AB, Armstrong D, Salinas CA. Characteristics of the patients who gain weigh while on pioglitazone treatment. Diabetes, 2001,50(Suppl 2):A120.
8Hiroshi H, Toshihide K, Yukihiro Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism, 2002,51:314-317.
9Lefebvre AM, Laville M, Vega N, et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes, 1998,47:98-103.
10Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferators-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest, 1997,100:3149-3153.